SEC Comment Letter 0000000000-23-005069 to Paratek Pharmaceuticals, Inc. (CIK 0001178711)
Paratek Pharmaceuticals, Inc. (CIK 0001178711)
Date: May 12, 2023 · CIK: 0001178711 · Accession: 0000000000-23-005069
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271780
Letter
United States securities and exchange commission logo May 12, 2023 Evan Loh, M.D. Chief Executive Officer Paratek Pharmaceuticals, Inc. 75 Park Plaza Boston, MA 02116 Re:Paratek Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 9, 2023 File No. 333-271780 Dear Evan Loh, M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas J. Danielski, Esq.
Show Raw Text
United States securities and exchange commission logo
May 12, 2023
Evan Loh, M.D.
Chief Executive Officer
Paratek Pharmaceuticals, Inc.
75 Park Plaza
Boston, MA 02116
Re:Paratek Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 9, 2023
File No. 333-271780
Dear Evan Loh, M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Thomas J. Danielski, Esq.